Journey Medical Corp shared its third-quarter results, showing $19.0 million in total sales and a big jump in Emrosi® sales.

Nov 12, 2026, 4:11 PM ETResultsRead the original at SEC EDGAR

Good for DERM

Journey Medical grew sales and Emrosi sales, increased the share of sales left after product costs, and narrowed its loss. Cash fell from $24.1 million to $22.3 million, but stronger sales and a smaller loss point to improvement.

DERM · Journey Medical Corporation

AI read · Good for DERM

The AI's read

That gives Journey Medical stronger sales from its key growth product, and more of each sales dollar remained after product costs. The smaller loss adds support. Cash fell from $24.1 million to $22.3 million, and the company still lost money, but sales and results improved overall.

Get alerts for DERM

Follow Journey Medical Corporation (DERM) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for DERM

Free on the App Store and Google Play, or on the web.